SCHEMBL9890752

SCHEMBL9890752

CNC(=O)Cc1ccccc1-c1cc(F)ccc1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
CSNK1D P48730 1/20 0.41
KCNA5 P22460 2/20 0.40
KCNK3 O14649 1/20 0.40
KCNK5 O95279 1/20 0.40
KCNK17 Q96T54 1/20 0.40
KCNK9 Q9NPC2 1/20 0.40
ALDH1A1 P00352 3/20 0.39
LMNA P02545 2/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 3/20 0.38
HTR7 P34969 1/20 0.38
ABL1 P00519 2/20 0.38
MAPT P10636 2/20 0.37
RAB9A P51151 2/20 0.37
PKM P14618 1/20 0.37
RXRA P19793 1/20 0.37
PPARG P37231 1/20 0.37
MAPK1 P28482 1/20 0.37
MEN1 O00255 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890755 0.89 GRIN1 (0.42) SMN1; SMN2CSNK1DKCNA5KCNK3KCNK5
SCHEMBL9890711 0.84 HPGD (0.42) SMN1; SMN2ALDH1A1GAAKMT2ARAB9A
SCHEMBL9890744 0.83 SLC9A1 (0.41) SMN1; SMN2CSNK1DLMNAABL1MAPT
SCHEMBL9892661 0.83 P2RX7 (0.42) SMN1; SMN2CSNK1DKCNA5KCNK3KCNK5
SCHEMBL9890732 0.82 ALDH1A1 (0.43) SMN1; SMN2KCNA5KCNK3KCNK5KCNK17
SCHEMBL9892682 0.80 P2RX7 (0.42) SMN1; SMN2KCNA5KCNK3KCNK5KCNK17
SCHEMBL9890731 0.80 LMNA (0.48) SMN1; SMN2KCNA5ALDH1A1LMNAMAPT
SCHEMBL12201835 0.80 SMN1; SMN2 (0.42) SMN1; SMN2ALDH1A1LMNAGAAKMT2A
SCHEMBL2391383 0.80 SLC6A4 (0.49) SMN1; SMN2KCNA5ALDH1A1LMNAKMT2A
SCHEMBL2395314 0.79 RAB9A (0.49) SMN1; SMN2ALDH1A1LMNAGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 SMN1; SMN2 2980/4885CSNK1D 3595/4885KCNA5 41/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 SMN1; SMN2 2980/4885CSNK1D 3595/4885KCNA5 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.